Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1586/14787210.2013.811924 | ||||
| Año | 2013 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Enterobacteriaceae and non fermenting Gram-negative bacilli have become a threat to public health, in part due to their resistance to multiple antibiotic classes, which ultimately have led to an increase in morbidity and mortality. -lactams are currently the mainstay for combating infections caused by these microorganisms, and -lactamases are the major mechanism of resistance to this class of antibiotics. Within the -lactamases, carbapenemases pose one of the gravest threats, as they compromise one of our most potent lines of defense, the carbapenems. Carbapenemases are being continuously identified worldwide; and in Latin America, numerous members of these enzymes have been reported. In this region, the high incidence of reports implies that carbapenemases have become a menace and that they are an issue that must be carefully studied and analyzed.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Maya, Juan J. | Hombre |
CIDEIM Int Ctr Med Res & Training - Colombia
Centro Internacional de Entrenamiento e Investigaciones Médicas - Colombia |
| 2 | Ruiz, Sory J. | - |
CIDEIM Int Ctr Med Res & Training - Colombia
Centro Internacional de Entrenamiento e Investigaciones Médicas - Colombia |
| 3 | Blanco, Victor M. | Hombre |
CIDEIM Int Ctr Med Res & Training - Colombia
Centro Internacional de Entrenamiento e Investigaciones Médicas - Colombia |
| 4 | Gotuzzo, E. | Hombre |
Hosp Nacl Cayetano Heredia - Perú
Hospital Nacional Cayetano Heredia - Perú |
| 5 | Guzman-Blanco, Manuel | Hombre |
Hospital Vargas de Caracas y Centro Medico de Caracas - México
|
| 6 | Labarca, Jaime | Hombre |
Pontificia Universidad Católica de Chile - Chile
|
| 7 | COSTA-SALLES, MAURO JOSE | Hombre |
Santa Casa Sao Paulo Sch Med - Brasil
Santa Casa de São Paulo School of Medicine - Brasil |
| 8 | Quinn, John P. | Hombre |
Astra Zeneca - Estados Unidos
AstraZeneca - Reino Unido |
| 9 | VILLEGAS-BOTERO, MARIA VIRGINIA | Mujer |
CIDEIM Int Ctr Med Res & Training - Colombia
Centro Internacional de Entrenamiento e Investigaciones Médicas - Colombia |
| Fuente |
|---|
| Novartis |
| Pfizer Inc. |
| Pfizer |
| AstraZeneca |
| Merck Sharp Dohme |
| Merck |
| Johnson Johnson |
| MSD Inc. |
| sanofi-aventis Inc. |
| AstraZeneca Colombia SA |
| Novartis Inc |
| United Medicals Brazil |
| Janssen-Cilag SA |
| Merck Colombia |
| Merck Sharp Dhome |
| BD |
| Pfizer SA |
| Agradecimiento |
|---|
| MV Villegas has received sponsorship for research by Merck Sharp & Dohme, Merck Colombia, Janssen-Cilag SA, Novartis, Pfizer SA and AstraZeneca Colombia SA. E Gotuzzo has been a consultant to Pfizer and has received research funds from Johnson & Johnson. M Guzman-Blanco is a member of advisory boards sponsored by Pfizer, Merck and BD. He has received research grants from AstraZeneca, Novartis. M Salles has received sponsorship for research by Novartis Inc, Pfizer Inc., MSD Inc., sanofi-aventis Inc. and United Medicals Brazil. J Labarca has been member of advisory boards for Merck Sharp & Dhome and Pfizer, has received research funds from Merck Sharp & Dhome, and has participated in clinical studies for Sanofi Pasteur. JP Quinn is an employee of AstraZeneca. JJ Maya, SJ Ruiz and VM Blanco report no conflicts of interests. None of the aforementioned companies funded or were involved in the elaboration of this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. |
| MV Villegas has received sponsorship for research by Merck Sharp & Dohme, Merck Colombia, Janssen-Cilag SA, Novartis, Pfizer SA and AstraZeneca Colombia SA. E Gotuzzo has been a consultant to Pfizer and has received research funds from Johnson & Johnson. M Guzman-Blanco is a member of advisory boards sponsored by Pfizer, Merck and BD. He has received research grants from AstraZeneca, Novartis. M Salles has received sponsorship for research by Novartis Inc, Pfizer Inc., MSD Inc., sanofi-aventis Inc. and United Medicals Brazil. J Labarca has been member of advisory boards for Merck Sharp & Dhome and Pfizer, has received research funds from Merck Sharp & Dhome, and has participated in clinical studies for Sanofi Pasteur. JP Quinn is an employee of AstraZeneca. JJ Maya, SJ Ruiz and VM Blanco report no conflicts of interests. None of the aforementioned companies funded or were involved in the elaboration of this manuscript. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. |